U.S., April 30 -- ClinicalTrials.gov registry received information related to the study (NCT06948214) titled 'Phase 3 Study of LUM-201 in Children With Growth Hormone Deficiency' on April 21.
Brief Summary: This is a multi-national trial. The goals of the trial are to study LUM-201 as a treatment for Pediatric Growth Hormone Deficiency (PGHD) in naive to treatment children and validate a predictive enrichment marker (PEM) strategy to select subjects likely to respond to therapy with LUM-201.
Study Start Date: Aug., 2025
Study Type: INTERVENTIONAL
Condition:
Growth Hormone Deficiency (GHD)
Intervention:
DRUG: LUM-201
1.6 mg/kg/day, administered orally once daily
OTHER: Matched Placebo (Capsules)
Administered orally once daily
Recr...